CAS 155405-80-4
:Metil 4-[2-(2-amino-4,7-diidro-4-oxo-3H-pirrolo[2,3-d]pirimidin-5-il)etil]benzoato
- 1H-Pyrrolo[2,3-d]pyrimidine, benzoic acid deriv.
- Methyl 4-[2-(2-Amino-4-Oxo-1,7-Dihydropyrrolo[4,5-E]Pyrimidin-5-Yl)Ethyl]Benzoate
- Methyl 4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoate
- Methyl 4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoate
- Methyl 4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoate
- benzoic acid, 4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-, methyl ester
- benzoic acid, 4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-, methyl ester
Benzoic acid, 4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-, methyl ester
CAS:Fórmula:C16H16N4O3Pureza:98%Cor e Forma:SolidPeso molecular:312.3232Methyl 4-(2-(2-Amino-4-Oxo-4,7-Dihydro-3H-Pyrrolo[2,3-d]Pyrimidin-5-yl)Ethyl)Benzoate
CAS:Methyl 4-(2-(2-Amino-4-Oxo-4,7-Dihydro-3H-Pyrrolo[2,3-d]Pyrimidin-5-yl)Ethyl)BenzoatePureza:99%Peso molecular:312.32g/molMethyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate
CAS:Pureza:95.0%Peso molecular:312.3290100097656Methyl 4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoate
CAS:Fórmula:C16H16N4O3Pureza:>98.0%(T)(HPLC)Cor e Forma:White to Light yellow to Light orange powder to crystalPeso molecular:312.33Pemetrexed acid methyl ester
CAS:Produto ControladoApplications An intermediate in the preparation of Pemetrexed Disodium (P219500) and its derivatives as anticancer agents.
References Min, T. et al.: Med. Chem. Res., 18, 495 (2009); Ma, Y. et al.: Zhong. Xin. Zaz., 16, 134 (2007);Fórmula:C16H16N4O3Cor e Forma:NeatPeso molecular:312.32Methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate
CAS:Methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate is a prodrug that is hydrolyzed to form the active drug pemetrexed disodium. The drug has been shown to be effective for the treatment of cancer and has been used in clinical trials for patients with lung cancer. The conversion of this prodrug to its active form occurs through a hydrolysis reaction at high temperature and by saponification with sodium hydroxide. Methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3 - d]pyrimidin -5 -yl)ethyl)benzoate can also be converted into its active form by enzymatic action using ester
Pureza:Min. 95%Ref: 3D-FM41972
Produto descontinuado







